ECSP23070234A - Anti-cd30l antibodies and uses thereof - Google Patents

Anti-cd30l antibodies and uses thereof

Info

Publication number
ECSP23070234A
ECSP23070234A ECSENADI202370234A ECDI202370234A ECSP23070234A EC SP23070234 A ECSP23070234 A EC SP23070234A EC SENADI202370234 A ECSENADI202370234 A EC SENADI202370234A EC DI202370234 A ECDI202370234 A EC DI202370234A EC SP23070234 A ECSP23070234 A EC SP23070234A
Authority
EC
Ecuador
Prior art keywords
cd30l antibodies
cd30l
antibodies
ibd
disorders
Prior art date
Application number
ECSENADI202370234A
Other languages
English (en)
Inventor
Johan Fransson
Olivier Laurent
Burton Barnett
Mark Renshaw
Jessie-Farah Fecteau
Original Assignee
Dr Falk Pharma Gmbh
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh, Prometheus Biosciences Inc filed Critical Dr Falk Pharma Gmbh
Publication of ECSP23070234A publication Critical patent/ECSP23070234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se describen anticuerpos anti-CD30L y composiciones farmacéuticas para el tratamiento de enfermedades y trastornos autoinmunitarios tales como la enteropatía inflamatoria (IBD), incluida la enfermedad de Crohn (CD) y la colitis ulcerosa (UC).
ECSENADI202370234A 2021-02-17 2023-09-14 Anti-cd30l antibodies and uses thereof ECSP23070234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17

Publications (1)

Publication Number Publication Date
ECSP23070234A true ECSP23070234A (es) 2023-10-31

Family

ID=82931610

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202370234A ECSP23070234A (es) 2021-02-17 2023-09-14 Anti-cd30l antibodies and uses thereof

Country Status (20)

Country Link
US (3) US20240254246A1 (es)
EP (1) EP4294840A4 (es)
JP (2) JP7559257B2 (es)
KR (1) KR20230157356A (es)
CN (2) CN117255802A (es)
AR (1) AR124895A1 (es)
AU (1) AU2022224561A1 (es)
BR (1) BR112023016445A2 (es)
CA (1) CA3208060A1 (es)
CL (1) CL2023002393A1 (es)
CO (1) CO2023011962A2 (es)
CR (1) CR20230445A (es)
EC (1) ECSP23070234A (es)
GE (4) GEAP202416351A (es)
IL (1) IL305146A (es)
JO (1) JOP20230186A1 (es)
MX (1) MX2023009621A (es)
PE (1) PE20231680A1 (es)
TW (1) TW202302637A (es)
WO (1) WO2022177963A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358963B2 (en) 2019-12-24 2025-07-15 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
MX2023009621A (es) 2021-02-17 2023-10-31 Prometheus Biosciences Inc Anticuerpos anti-cd30l y usos de estos.
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof
WO2024026271A1 (en) * 2022-07-25 2024-02-01 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
TW202513588A (zh) * 2023-09-12 2025-04-01 美商安進公司 抗ｃｄ３０ｌ抗體及其用途
CN122055382A (zh) * 2023-10-03 2026-05-15 国立大学法人京都大学 靶向人cd153的抗体和嵌合抗原受体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
DK0615451T3 (da) * 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2536086C (en) 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
EP2769321B1 (en) * 2011-10-21 2016-06-01 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
DK3431492T3 (da) * 2012-04-27 2021-03-08 Amgen Inc Humane cd30-ligandantigen-bindende proteiner
WO2014168664A2 (en) 2013-01-18 2014-10-16 Lord Corporation Active vibration control devices, systems, and methods
JP7628764B2 (ja) * 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
US20210208162A1 (en) 2016-01-19 2021-07-08 Global Down Syndrome Foundation Down syndrome biomarkers and uses thereof
MA52251A (fr) * 2018-04-30 2021-02-17 Cedars Sinai Medical Center Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
MX2023009621A (es) 2021-02-17 2023-10-31 Prometheus Biosciences Inc Anticuerpos anti-cd30l y usos de estos.

Also Published As

Publication number Publication date
JOP20230186A1 (ar) 2023-08-09
CL2023002393A1 (es) 2024-03-22
CN117255802A (zh) 2023-12-19
GEAP202416351A (en) 2024-02-12
KR20230157356A (ko) 2023-11-16
US20240254246A1 (en) 2024-08-01
GEAP202516710A (en) 2025-05-13
CA3208060A1 (en) 2022-08-25
US11866505B2 (en) 2024-01-09
GEAP202616911A (en) 2026-04-27
JP7559257B2 (ja) 2024-10-01
CR20230445A (es) 2023-11-14
WO2022177963A1 (en) 2022-08-25
US20240092923A1 (en) 2024-03-21
US12516126B2 (en) 2026-01-06
GEP20257791B (en) 2025-09-10
US20230060624A1 (en) 2023-03-02
BR112023016445A2 (pt) 2023-12-12
JP2025004013A (ja) 2025-01-14
AU2022224561A9 (en) 2023-10-05
EP4294840A1 (en) 2023-12-27
IL305146A (en) 2023-10-01
AU2022224561A1 (en) 2023-09-28
PE20231680A1 (es) 2023-10-19
MX2023009621A (es) 2023-10-31
AR124895A1 (es) 2023-05-17
TW202302637A (zh) 2023-01-16
JP2024509746A (ja) 2024-03-05
CO2023011962A2 (es) 2023-09-29
CN118047872A (zh) 2024-05-17
EP4294840A4 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
CO2023011962A2 (es) Anticuerpos anti-cd30l y usos de estos
ECSP23070237A (es) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
NZ787680A (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
ECSP15038626A (es) A61k 30/395
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
EP3414573A4 (en) NOVEL ANTI-LAM AND ANTI-PIM6 / LAM MONOCLONAL ANTIBODIES FOR THE DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS
CL2022001016A1 (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos
MX2020007917A (es) Derivados de tiofeno no condensados y sus usos.
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
CO2020005200A2 (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين
MX2025001038A (es) Anticuerpos anti-cd30l, formulaciones de estos, y uso de los mismos
MX2023013083A (es) Compuestos y usos de los mismos.
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
AR111845A1 (es) Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
EA202191724A1 (ru) Ингибиторы пути jak1 для лечения заболевания желудочно-кишечного тракта